Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.45 |
| ▸ | ACACA | Q13085 | 6/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429518 | 0.83 | ACACB (0.53) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL5420220 | 0.83 | ACACB (0.46) | ACACBACACA | |
| SCHEMBL9273866 | 0.82 | ALDH1A1 (0.41) | ACACBACACALMNA | |
| SCHEMBL4743684 | 0.80 | FBP1 (0.51) | ACACBACACACYP2C9CYP2C19LMNA | |
| SCHEMBL26298581 | 0.80 | ALDH1A1 (0.49) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL11036465 | 0.80 | ACACB (0.44) | ACACBACACALMNA | |
| SCHEMBL5426770 | 0.79 | ACACB (0.48) | ACACBACACAGCKCYP2C9CYP2C19 | |
| SCHEMBL1367047 | 0.79 | — | — | |
| SCHEMBL22967570 | 0.79 | ACACB (0.46) | ACACBACACALMNA | |
| SCHEMBL25369458 | 0.77 | FBP1 (0.43) | ACACBACACALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748627-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8735595-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| CN-101384568-B | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LAB | 2012-12-12 | — | — | CN | disclosed |
| US-7928243-B2 | e.g. N-{(2Z)-3-[4-(4-isopropoxyphenoxy)phenyl]-1-methylprop-2-enyl}acetamide; antidiabetic agent; type II diabetes, atherosclerosis and cardiovascular diseases | ABBOTT LABORATORIES (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1991536-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070219251-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007095603-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219251-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885GCK 403/4885 |
| US-20080161368-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885GCK 240/4885 |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885GCK 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.